Type 1 diabetes mellitus caused by treatment with interferon-β

被引：17

作者：

Kado, S ^{[1
]}

Miyamoto, J ^{[1
]}

Komatsu, N ^{[1
]}

Iwaki, Y ^{[1
]}

Ozaki, H ^{[1
]}

Taguchi, H ^{[1
]}

Kure, M ^{[1
]}

Sarashina, G ^{[1
]}

Watanabe, T ^{[1
]}

Katsura, Y ^{[1
]}

Nemoto, Y ^{[1
]}

Noritake, M ^{[1
]}

Matsuoka, T ^{[1
]}

机构：

[1] Tokyo Med Univ, Dept Internal Med 5, Inashiki, Ibaragi 3000395, Japan

来源：

INTERNAL MEDICINE | 2000年 / 39卷 / 02期

关键词：

GAD antibody; chronic hepatitis; hepatitis C virus; human leukocyte antigen;

D O I：

10.2169/internalmedicine.39.146

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 57-year-old man was referred to our outpatient clinic after interferon-beta (IFN-beta) treatment for 7 weeks. While IFN-beta therapy was continued in our outpatient clinic, his blood glucose level increased gradually, and he was admitted to our hospital for hyperglycemia. The patient was prescribed a 1,600-kcal diet and intensive insulin therapy was performed. GAD antibody became positive 15 months after the start of IFN therapy, and disappeared 27 months after the start of IFN therapy. Insulin secretion was depleted and the patient had HLA-DR4, B54, and DRB1*0405, This appears to be a case of type 1 diabetes mellitus induced by administration of IFN-beta alone.

引用

页码：146 / 149

页数：4

共 50 条

[31] Solution behavior of a novel type 1 interferon, interferon-τ
Katayama, DS
Nayar, R
Chou, DK
Campos, J
Cooper, J
Vander Velde, DG
Villarete, L
Liu, CP
Manning, MC
JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (12) : 2703 - 2715
[32] Progression of type 1 diabetes from the prediabetic stage is controlled by interferon-α signaling
Marro, Brett S.
Ware, Brian C.
Zak, Jaroslav
de la Torre, Juan Carlos
Rosen, Hugh
Oldstone, Michael B. A.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (14) : 3708 - 3713
[33] Investigation of interferon-γ and interleukin-4 gene polymorphism in type 1 diabetes
Jahromi, MM
Millward, BA
Demaine, AG
DIABETOLOGIA, 1999, 42 : A90 - A90
[34] Natural killer cells are required for accelerated type 1 diabetes driven by interferon-β
Alba, A.
Planas, R.
Clemente, X.
Carrillo, J.
Ampudia, R.
Puertas, M. -C.
Pastor, X.
Tolosa, E.
Pujol-Borrell, R.
Verdaguer, J.
Vives-Pi, M.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2008, 151 (03): : 467 - 475
[35] Progression of Type 1 Diabetes from the Prediabetic Stage Is Controlled by Interferon-α Signaling
Marro, Brett S.
Ware, Brian C.
Zak, Jaroslav
De la Torre, Juan Carlos
Rosen, Hugh
Oldstone, Michael B. A.
DIABETES, 2017, 66 : LB67 - LB67
[36] Interferon-α as a mediator of polyinosinic:polycytidylic acid-induced type 1 diabetes
Devendra, D
Jasinski, J
Melanitou, E
Nakayama, M
Li, M
Hensley, B
Paronen, J
Moriyama, H
Miao, DM
Eisenbarth, GS
Liu, E
DIABETES, 2005, 54 (09) : 2549 - 2556
[37] Pramlintide in the treatment of type 1 and type 2 diabetes mellitus
Ryan, GJ
Jobe, LJ
Martin, R
CLINICAL THERAPEUTICS, 2005, 27 (10) : 1500 - 1512
[38] Polymorphisms of interferon-γ gene are associated with type I diabetes
Jahromi, MM
Millward, BA
Demaine, AG
DIABETOLOGIA, 1998, 41 : A79 - A79
[39] Glycine treatment decreases proinflammatory cytokines and increases interferon-γ in patients with Type 2 diabetes
Cruz, M.
Maldonado-Bernal, C.
Mondragon-Gonzalez, R.
Sanchez-Barrera, R.
Wacher, N. H.
Carvajal-Sandoval, G.
Kumate, J.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2008, 31 (08) : 694 - 699
[40] Glycine treatment decreases proinflammatory cytokines and increases interferon-γ in patients with Type 2 diabetes
M. Cruz
C. Maldonado-Bernal
R. Mondragón-Gonzalez
R. Sanchez-Barrera
N. H. Wacher
G. Carvajal-Sandoval
J. Kumate
Journal of Endocrinological Investigation, 2008, 31 : 694 - 699

← 1 2 3 4 5 →